• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Serum magnesium level and arterial calcification in end-stage renal disease.

作者信息

Meema H E, Oreopoulos D G, Rapoport A

机构信息

Department of Radiology, Toronto Western Hospital, Ontario, Canada.

出版信息

Kidney Int. 1987 Sep;32(3):388-94. doi: 10.1038/ki.1987.222.

DOI:10.1038/ki.1987.222
PMID:3669498
Abstract

In this paper we examine the relationship of serum levels of Ca, P, Ca X P, P/Mg, Ca X P/Mg, alkaline phosphatase, and iPTH to the development or regression of peripheral arterial calcifications (AC) in 44 patients with end-stage renal disease being treated by continuous ambulatory peritoneal dialysis (CAPD). The average follow-up time of this longitudinal study was 27 months (range 6-67 months). The patients were divided into two groups: Group A, those showing one or more increases of AC; and Group B, patients in whom AC either did not develop or decreased during the follow-up. There was no significant difference in serum Ca, P, Ca X P, alkaline phosphatase of iPTH between the two groups. However, serum Mg was significantly lower in Group A than in Group B (2.69 +/- 0.52 and 3.02 +/- 0.51 mg/dl, respectively, P less than 0.001), while the ratios P/Mg and Ca X P/Mg were significantly higher. Our observations suggest that in end-stage renal disease hypermagnesemia may retard the development of arterial calcifications.

摘要

相似文献

1
Serum magnesium level and arterial calcification in end-stage renal disease.
Kidney Int. 1987 Sep;32(3):388-94. doi: 10.1038/ki.1987.222.
2
Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.使用低镁腹膜透析液的持续性非卧床腹膜透析(CAPD)患者血清甲状旁腺激素与镁水平之间的关系。
Korean J Intern Med. 2002 Jun;17(2):114-21. doi: 10.3904/kjim.2002.17.2.114.
3
Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial.碳酸镁用于血液透析患者的磷控制:一项随机对照试验。
Int Urol Nephrol. 2008;40(1):193-201. doi: 10.1007/s11255-007-9300-0. Epub 2008 Jan 10.
4
Phosphorus control in peritoneal dialysis patients.腹膜透析患者的磷控制
Kidney Int Suppl. 2008 Apr(108):S152-8. doi: 10.1038/sj.ki.5002617.
5
Renal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis.
Q J Med. 1985 Jan;54(213):29-48.
6
Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.司维拉姆对慢性血液透析患者血管钙化进展的影响。
Nephron Clin Pract. 2008;108(4):c278-83. doi: 10.1159/000127361. Epub 2008 Apr 22.
7
[Cardiovascular risk in women with chronic renal failure: mammographic study of vascular calcifications].[慢性肾衰竭女性的心血管风险:乳腺钼靶血管钙化研究]
Radiologia. 2008 Jan-Feb;50(1):54-60. doi: 10.1016/s0033-8338(08)71929-5.
8
Association between serum magnesium and risk factors of cardiovascular disease in hemodialysis patients.血液透析患者血清镁与心血管疾病危险因素之间的关联。
Iran J Kidney Dis. 2013 Jan;7(1):47-52.
9
A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.帕立骨化醇治疗终末期肾病疗效与安全性的长期多中心研究
Clin Nephrol. 2001 Oct;56(4):315-23.
10
Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: possible risk of vitamin D(3) analog administration in dialysis patients with end-stage renal disease.甲状旁腺功能减退通过钙代谢紊乱加重心血管并发症:终末期肾病透析患者使用维生素D(3)类似物的潜在风险。
Nephron. 2000 Jan;84(1):13-20. doi: 10.1159/000045533.

引用本文的文献

1
Cardiovascular and All-Cause Mortality Is Affected by Serum Magnesium and Diet Pattern in a Cohort of Dialysis Patients.在一组透析患者中,血清镁和饮食模式会影响心血管疾病和全因死亡率。
J Clin Med. 2024 Jul 10;13(14):4024. doi: 10.3390/jcm13144024.
2
Dietary magnesium supplementation in cats with chronic kidney disease: A prospective double-blind randomized controlled trial.慢性肾脏病猫的膳食镁补充:一项前瞻性双盲随机对照试验。
J Vet Intern Med. 2024 Jul-Aug;38(4):2180-2195. doi: 10.1111/jvim.17134. Epub 2024 Jul 1.
3
Lower serum magnesium is a predictor of left ventricular hypertrophy in patients on dialysis.
血清镁水平较低是透析患者左心室肥厚的一个预测指标。
Int Urol Nephrol. 2023 Apr;55(4):1015-1023. doi: 10.1007/s11255-022-03391-2. Epub 2022 Oct 24.
4
Dialysate Magnesium and Coronary Artery Calcification, Bone Mineral Density, and Cramping in Maintenance Hemodialysis: A Quasi-experimental Study.透析液镁与维持性血液透析患者的冠状动脉钙化、骨矿物质密度及痉挛:一项准实验研究
Kidney Med. 2021 Oct 12;4(2):100374. doi: 10.1016/j.xkme.2021.08.009. eCollection 2022 Feb.
5
Gut Microbiome, Functional Food, Atherosclerosis, and Vascular Calcifications-Is There a Missing Link?肠道微生物群、功能性食品、动脉粥样硬化与血管钙化——存在缺失的环节吗?
Microorganisms. 2021 Sep 9;9(9):1913. doi: 10.3390/microorganisms9091913.
6
Nutraceutical, Dietary, and Lifestyle Options for Prevention and Treatment of Ventricular Hypertrophy and Heart Failure.营养保健品、饮食和生活方式选择在预防和治疗心室肥厚和心力衰竭中的作用。
Int J Mol Sci. 2021 Mar 24;22(7):3321. doi: 10.3390/ijms22073321.
7
Low plasma magnesium concentration and future abdominal aortic calcifications in moderate chronic kidney disease.血浆镁浓度低与中重度慢性肾脏病患者的未来腹主动脉钙化。
BMC Nephrol. 2021 Feb 25;22(1):71. doi: 10.1186/s12882-021-02267-4.
8
The Role of Disturbed Mg Homeostasis in Chronic Kidney Disease Comorbidities.镁稳态紊乱在慢性肾脏病合并症中的作用
Front Cell Dev Biol. 2020 Nov 12;8:543099. doi: 10.3389/fcell.2020.543099. eCollection 2020.
9
Serum magnesium, bone-mineral metabolism markers and their interactions with kidney function on subsequent risk of peripheral artery disease: the Atherosclerosis Risk in Communities Study.血清镁、骨矿物质代谢标志物及其与肾功能的相互作用与外周动脉疾病的后续风险:社区动脉粥样硬化风险研究。
Nephrol Dial Transplant. 2020 Nov 1;35(11):1878-1885. doi: 10.1093/ndt/gfaa029.
10
Vascular disease in the lower limb in type 1 diabetes.1型糖尿病患者的下肢血管疾病
Cardiovasc Endocrinol Metab. 2019 Feb 13;8(1):39-46. doi: 10.1097/XCE.0000000000000168. eCollection 2019 Mar.